Lexaria Bioscience (LEXX) Income from Non-Controlling Interests (2014 - 2026)
Lexaria Bioscience (LEXX) posted Income from Non-Controlling Interests of -$1779.0 for Q2 2026, up 35.38% sequentially from -$2753.0 in Q1 2026, and down 17.5% YoY from -$2156.4 in Q2 2025.
Lexaria Bioscience (LEXX) Income from Non-Controlling Interests (2014 - 2026) Analysis & Trends
Lexaria Bioscience has reported Income from Non-Controlling Interests for 12 years, with the latest figure at -$1779.0 in Q2 2026.
- Quarterly Income from Non-Controlling Interests fell 17.5% year-over-year to -$1779.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was -$8418.0 (up 15.69% YoY) and the FY2025 annual result came in at -$9593.0, up 27.92% from the prior year.
- Income from Non-Controlling Interests grew to -$1779.0 in Q2 2026 per LEXX's latest filing, from -$2753.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at -$1390.0 in Q3 2025 and troughed at -$45696.0 in Q3 2022.
- A 5-year average of -$10086.7 and a median of -$3477.0 in 2024 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2022 and 2024: Income from Non-Controlling Interests sank 270.62% in 2022, then surged 81.63% in 2024.
- Over 5 years, Income from Non-Controlling Interests stood at -$13362.0 in 2022, then jumped by 57.23% to -$5715.0 in 2023, then soared by 48.75% to -$2929.0 in 2024, then rose by 14.78% to -$2496.0 in 2025, then increased by 28.73% to -$1779.0 in 2026.
- According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$1779.0, -$2753.0, and -$2496.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | -1,779.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -1,779.00 |
| Feb 28, 2026 | -2,753.00 |
| Nov 30, 2025 | -2,496.00 |
| Aug 31, 2025 | -1,390.00 |
| May 31, 2025 | -1,514.00 |
| Feb 28, 2025 | -3,760.00 |
| Nov 30, 2024 | -2,929.00 |
| Aug 31, 2024 | -1,781.00 |
| May 31, 2024 | -2,619.00 |
| Feb 29, 2024 | -3,194.00 |
| Nov 30, 2023 | -5,715.00 |
| Aug 31, 2023 | -9,696.00 |
| May 31, 2023 | -12,061.00 |
| Feb 28, 2023 | -12,507.00 |
| Nov 30, 2022 | -13,362.00 |
| Aug 31, 2022 | -45,696.00 |
| May 31, 2022 | -35,413.00 |
| Feb 28, 2022 | -22,895.00 |
| Nov 30, 2021 | -10,325.00 |
| Aug 31, 2021 | -124,573.00 |